Loading...
Header Logo
Keywords
Last Name
Institution

ARLENE ODELIA SIEFKER-RADTKE

TitleAssociate Professor
InstitutionMD Anderson
DepartmentGenitourinary Medical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Loriot Y, Necchi A, Siefker-Radtke AO. Erdafitinib in Urothelial Carcinoma. Reply. N Engl J Med. 2019 10 17; 381(16):1594-1595. PMID: 31618553.
      View in: PubMed
    2. Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2019 07 25; 381(4):338-348. PMID: 31340094.
      View in: PubMed
    3. Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, Bhardwaj N, Horowitz A, Farkas AM, Mulholland D, Fischer BS, Oh WK, Sharma P, Zhu J, Galsky MD. Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. Eur Urol. 2019 Nov; 76(5):599-603. PMID: 31272788.
      View in: PubMed
    4. Ohyama C, Kojima T, Kondo T, Naya Y, Inoue T, Tomita Y, Eto M, Hisasue S, Uemura H, Obara W, Kikuchi E, Sharma P, Galsky MD, Siefker-Radtke A, Grossfeld G, Collette S, Gooden K, Kimura G. Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses. Int J Clin Oncol. 2019 Sep; 24(9):1089-1098. PMID: 31218529.
      View in: PubMed
    5. Sharma P, Siefker-Radtke A, de Braud F, Basso U, Calvo E, Bono P, Morse MA, Ascierto PA, Lopez-Martin J, Brossart P, Rohrberg K, Mellado B, Fischer BS, Meadows-Shropshire S, Callahan MK, Rosenberg J. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. J Clin Oncol. 2019 Jul 01; 37(19):1608-1616. PMID: 31100038.
      View in: PubMed
    6. Alhalabi O, Rafei H, Shah A, Siefker-Radtke A, Campbell M, Gao J. Targeting advanced urothelial carcinoma-developing strategies. Curr Opin Oncol. 2019 05; 31(3):207-215. PMID: 30844889.
      View in: PubMed
    7. Duplisea JJ, Petros FG, Li R, Fellman B, Guo CC, Czerniak BA, Siefker-Radtke AO, Araujo JC, Dinney CPN, Matin SF. Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urol Oncol. 2019 06; 37(6):354.e19-354.e26. PMID: 30777393.
      View in: PubMed
    8. Merseburger AS, Apolo AB, Chowdhury S, Hahn NM, Galsky MD, Milowsky MI, Petrylak D, Powles T, Quinn DI, Rosenberg JE, Siefker-Radtke A, Sonpavde G, Sternberg CN. SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. World J Urol. 2019 Jan; 37(1):95-105. PMID: 30238401.
      View in: PubMed
    9. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 09; 16(9):1041-1053. PMID: 30181416.
      View in: PubMed
    10. Wang L, Saci A, Szabo PM, Chasalow SD, Castillo-Martin M, Domingo-Domenech J, Siefker-Radtke A, Sharma P, Sfakianos JP, Gong Y, Dominguez-Andres A, Oh WK, Mulholland D, Azrilevich A, Hu L, Cordon-Cardo C, Salmon H, Bhardwaj N, Zhu J, Galsky MD. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun. 2018 08 29; 9(1):3503. PMID: 30158554.
      View in: PubMed
    11. Dietrich B, Siefker-Radtke AO, Srinivas S, Yu EY. Systemic Therapy for Advanced Urothelial Carcinoma: Current Standards and Treatment Considerations. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:342-353. PMID: 30231356.
      View in: PubMed
    12. Wang G, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol. 2018 09; 79:57-65. PMID: 29763719.
      View in: PubMed
    13. Mmeje CO, Benson CR, Nogueras-González GM, Jayaratna IS, Gao J, Siefker-Radtke AO, Kamat AM, Dinney CP, Navai N, Shah JB. Determining the optimal time for radical cystectomy after neoadjuvant chemotherapy. BJU Int. 2018 07; 122(1):89-98. PMID: 29569824.
      View in: PubMed
    14. Siefker-Radtke A, Curti B. Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nat Rev Urol. 2018 02; 15(2):112-124. PMID: 29205200.
      View in: PubMed
    15. Siefker-Radtke AO, Apolo AB, Bivalacqua TJ, Spiess PE, Black PC. Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma. J Urol. 2018 05; 199(5):1129-1142. PMID: 29113841.
      View in: PubMed
    16. Özdemir BC, Siefker-Radtke AO, Campbell MT, Subudhi SK. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. Eur Urol Focus. 2018 04; 4(3):442-454. PMID: 29056275.
      View in: PubMed
    17. Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 10; 15(10):1240-1267. PMID: 28982750.
      View in: PubMed
    18. Shah AY, Gao J, Siefker-Radtke AO. Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer. Immunotherapy. 2017 09; 9(10):781-784. PMID: 28877627.
      View in: PubMed
    19. Wang G, Huang H, Kamat AM, Siefker-Radtke A, Dinney CP, Troncoso P, Czerniak B, Guo CC. High-grade neuroendocrine carcinoma of the urachus-report of 3 cases. Hum Pathol. 2017 09; 67:126-133. PMID: 28823575.
      View in: PubMed
    20. Metcalfe MJ, Ferguson JE, Li R, Xiao L, Guo CC, Czerniak BA, Siefker-Radtke A, Pretzsch SM, Navai N, McConkey DJ, Kamat AM, Campbell M, Dinney C. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus. 2017 12; 3(6):577-583. PMID: 28753816.
      View in: PubMed
    21. Campbell MT, Shah AY, Matin SF, Siefker-Radtke AO. Optimizing management of upper tract urothelial carcinoma. Urol Oncol. 2017 07; 35(7):492-498. PMID: 28579283.
      View in: PubMed
    22. Siefker-Radtke AO, Campbell MT. Reply to B. Biswas et al. J Clin Oncol. 2017 06 20; 35(18):2097. PMID: 28471712.
      View in: PubMed
    23. Fox MD, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Zhang L, Dinney CP, Czerniak B, Guo CC. Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. Am J Clin Pathol. 2017 May 01; 147(5):500-506. PMID: 28371875.
      View in: PubMed
    24. Siefker-Radtke AO, Campbell MT. Now Is the Time for Perioperative Chemotherapy in Upper Tract Urothelial Cancer. J Clin Oncol. 2017 03 10; 35(8):816-817. PMID: 28165904.
      View in: PubMed
    25. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm MO, Bracarda S, Arranz JÁ, Pal S, Ohyama C, Saci A, Qu X, Lambert A, Krishnan S, Azrilevich A, Galsky MD. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 03; 18(3):312-322. PMID: 28131785.
      View in: PubMed
    26. Ochoa AE, Choi W, Su X, Siefker-Radtke A, Czerniak B, Dinney C, McConkey DJ. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer. Oncotarget. 2016 Dec 06; 7(49):80164-80174. PMID: 27845906.
      View in: PubMed
    27. Fernández MI, Williams SB, Willis DL, Slack RS, Dickstein RJ, Parikh S, Chiong E, Siefker-Radtke AO, Guo CC, Czerniak BA, McConkey DJ, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM. Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU Int. 2017 05; 119(5):684-691. PMID: 27753185.
      View in: PubMed
    28. Kim C, Gao J, Shannon VR, Siefker-Radtke A. Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition. BMJ Case Rep. 2016 Oct 26; 2016. PMID: 27797838.
      View in: PubMed
    29. Solomon JP, Lowenthal BM, Kader AK, Parsons JK, Flaig TW, Siefker-Radtke AO, Dyrskjøt L, Hansel DE. Challenges in the Diagnosis of Urothelial Carcinoma Variants: Can Emerging Molecular Data Complement Pathology Review? Urology. 2017 04; 102:7-16. PMID: 27769917.
      View in: PubMed
    30. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 10; 14(10):1213-1224. PMID: 27697976.
      View in: PubMed
    31. Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine. 2016 Oct; 12:105-117. PMID: 27612592.
      View in: PubMed
    32. Pal SK, Agarwal N, Boorjian SA, Hahn NM, Siefker-Radtke AO, Clark PE, Plimack ER. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. J Clin Oncol. 2016 09 20; 34(27):3346-8. PMID: 27458279.
      View in: PubMed
    33. Siefker-Radtke A, Zhang XQ, Guo CC, Shen Y, Pirollo KF, Sabir S, Leung C, Leong-Wu C, Ling CM, Chang EH, Millikan RE, Benedict WF. A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers. Mol Ther. 2016 Aug; 24(8):1484-91. PMID: 27480598.
      View in: PubMed
    34. Gakis G, Schubert T, Alemozaffar M, Bellmunt J, Bochner BH, Boorjian SA, Daneshmand S, Huang WC, Kondo T, Konety BR, Laguna MP, Matin SF, Siefker-Radtke AO, Shariat SF, Stenzl A. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016: treatment of localized high-risk disease. World J Urol. 2017 Mar; 35(3):327-335. PMID: 27043218.
      View in: PubMed
    35. Guo CC, Dadhania V, Zhang L, Majewski T, Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, Fuentes-Mattei E, Kamat AM, Dinney C, Siefker-Radtke A, Choi W, Baggerly KA, McConkey D, Weinstein JN, Czerniak B. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol. 2016 10; 70(4):611-620. PMID: 26988609.
      View in: PubMed
    36. Siefker-Radtke A. Editorial Comment. J Urol. 2016 06; 195(6):1696. PMID: 26970453.
      View in: PubMed
    37. Campbell MT, Siefker-Radtke AO, Gao J. The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration. Cancer J. 2016 Mar-Apr; 22(2):96-100. PMID: 27111904.
      View in: PubMed
    38. Siefker-Radtke AO, Campbell MT, Munsell MF, Harris DR, Carolla RL, Pagliaro LC. Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study. Urology. 2016 Mar; 89:83-9. PMID: 26723185.
      View in: PubMed
    39. Ho PL, Willis DL, Patil J, Xiao L, Williams SB, Melquist JJ, Tart K, Parikh S, Shah JB, Delacroix SE, Navai N, Siefker-Radtke A, Dinney CP, Pisters LL, Kamat AM. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. Urol Oncol. 2016 Feb; 34(2):59.e1-8. PMID: 26421586.
      View in: PubMed
    40. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2016 05; 69(5):855-62. PMID: 26343003.
      View in: PubMed
    41. Dhillon J, Liang Y, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol. 2015 Dec; 46(12):1808-14. PMID: 26364859.
      View in: PubMed
    42. McConkey DJ, Choi W, Ochoa A, Siefker-Radtke A, Czerniak B, Dinney CP. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. Hematol Oncol Clin North Am. 2015 Apr; 29(2):377-94, x-xi. PMID: 25836941.
      View in: PubMed
    43. Siefker-Radtke AO, Gao J. Towards effective adjuvant treatment for urothelial cancer. Lancet Oncol. 2015 Jan; 16(1):9-10. PMID: 25498220.
      View in: PubMed
    44. Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2015 Jun; 13(3):218-24. PMID: 25465491.
      View in: PubMed
    45. Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConkey DJ. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014 Jul; 11(7):400-10. PMID: 24960601.
      View in: PubMed
    46. Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radtke AO, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Al-Hawary M, Smith DC. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer. 2014 Sep 01; 120(17):2684-93. PMID: 24802654.
      View in: PubMed
    47. Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014 Jun 15; 120(12):1794-9. PMID: 24633966.
      View in: PubMed
    48. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014 Feb 10; 25(2):152-65. PMID: 24525232.
      View in: PubMed
    49. Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Küfer R, Hogendoorn PC, Netto G, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet. 2013 Dec; 45(12):1428-30. PMID: 24121789.
      View in: PubMed
    50. Wood DP. Re: A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. J Urol. 2013 Dec; 190(6):2019. PMID: 24209516.
      View in: PubMed
    51. Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014 Jan; 191(1):40-7. PMID: 23911605.
      View in: PubMed
    52. Qi W, White MC, Choi W, Guo C, Dinney C, McConkey DJ, Siefker-Radtke A. Inhibition of inducible heat shock protein-70 (hsp72) enhances bortezomib-induced cell death in human bladder cancer cells. PLoS One. 2013; 8(7):e69509. PMID: 23874968.
      View in: PubMed
    53. Galsky MD, Hendricks R, Svatek R, Bangs R, Hoffman-Censits J, Clement J, Dreicer R, Guancial E, Hahn N, Lerner SP, O'Donnell PH, Quale DZ, Siefker-Radtke A, Shipley W, Sonpavde G, Vaena D, Vinson J, Rosenberg J. Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer: a report from the Bladder Cancer Advocacy Network Clinical Trials Working Group. Cancer. 2013 Jun 01; 119(11):1994-8. PMID: 23456777.
      View in: PubMed
    54. Tran MN, Choi W, Wszolek MF, Navai N, Lee IL, Nitti G, Wen S, Flores ER, Siefker-Radtke A, Czerniak B, Dinney C, Barton M, McConkey DJ. The p63 protein isoform ?Np63a inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205. J Biol Chem. 2013 Feb 01; 288(5):3275-88. PMID: 23239884.
      View in: PubMed
    55. Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP, Siefker-Radtke AO. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013 May; 189(5):1656-61. PMID: 23159581.
      View in: PubMed
    56. Siefker-Radtke A. Urachal adenocarcinoma: a clinician's guide for treatment. Semin Oncol. 2012 Oct; 39(5):619-24. PMID: 23040259.
      View in: PubMed
    57. Siefker-Radtke AO, Dinney CP, Shen Y, Williams DL, Kamat AM, Grossman HB, Millikan RE. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results. Cancer. 2013 Feb 01; 119(3):540-7. PMID: 22914978.
      View in: PubMed
    58. Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013 Jan; 63(1):58-66. PMID: 22917984.
      View in: PubMed
    59. Marquis L, Tran M, Choi W, Lee IL, Huszar D, Siefker-Radtke A, Dinney C, McConkey DJ. p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells. Cancer Biol Ther. 2012 May; 13(7):477-86. PMID: 22361733.
      View in: PubMed
    60. Lynch SP, Shen Y, Kamat A, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. 2013 Aug; 64(2):307-13. PMID: 22564397.
      View in: PubMed
    61. Alva AS, Matin SF, Lerner SP, Siefker-Radtke AO. Perioperative chemotherapy for upper tract urothelial cancer. Nat Rev Urol. 2012 Apr 10; 9(5):266-73. PMID: 22487872.
      View in: PubMed
    62. Choi W, Shah JB, Tran M, Svatek R, Marquis L, Lee IL, Yu D, Adam L, Wen S, Shen Y, Dinney C, McConkey DJ, Siefker-Radtke A. p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One. 2012; 7(1):e30206. PMID: 22253920.
      View in: PubMed
    63. Tam Tam KB, George E, Cockrell K, Arany M, Speed J, Martin JN, Lamarca B, Granger JP. Endothelin type A receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance. Am J Obstet Gynecol. 2011 Apr; 204(4):330.e1-4. PMID: 12629346.
      View in: PubMed
    64. Rajput MZ, Kamat AM, Clavell-Hernandez J, Siefker-Radtke AO, Grossman HB, Dinney CP, Matin SF. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology. 2011 Jul; 78(1):61-7. PMID: 21354598.
      View in: PubMed
    65. Rodney AJ, Tannir NM, Siefker-Radtke AO, Liu P, Walsh GL, Millikan RE, Swisher SG, Tu SM, Pagliaro LC. Survival outcomes for men with mediastinal germ-cell tumors: the University of Texas M. D. Anderson Cancer Center experience. Urol Oncol. 2012 Nov-Dec; 30(6):879-85. PMID: 20933444.
      View in: PubMed
    66. Svatek RS, Shariat SF, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Müller SC, Izawa JI, Ficarra V, Sagalowsky AI, Schoenberg MP, Siefker-Radtke AO, Millikan RE, Dinney CP. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res. 2010 Sep 01; 16(17):4461-7. PMID: 20651056.
      View in: PubMed
    67. McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, Siefker-Radtke A, Dinney C, Czerniak B. Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol. 2010 Jul-Aug; 28(4):429-40. PMID: 20610280.
      View in: PubMed
    68. Siefker-Radtke A. Bladder cancer: can we move beyond chemotherapy? Curr Oncol Rep. 2010 Jul; 12(4):278-83. PMID: 20446067.
      View in: PubMed
    69. Matin SF, Margulis V, Kamat A, Wood CG, Grossman HB, Brown GA, Dinney CP, Millikan R, Siefker-Radtke AO. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. 2010 Jul 01; 116(13):3127-34. PMID: 20564621.
      View in: PubMed
    70. Childs MA, Wood CG, Spiess PE, Debiane LG, Hernandez M, Matin SF, Millikan RE, Siefker-Radtkie A, Scott SM, Pisters LL. Early results of chemotherapy with retroperitoneal lymph node dissection for isolated retroperitoneal recurrence of upper urinary tract urothelial carcinoma after nephroureterectomy. Can J Urol. 2010 Jun; 17(3):5184-9. PMID: 20566011.
      View in: PubMed
    71. Black PC, Dinney CP, Brown GA, Kassouf W, Siefker-Radtke AO, Munsell MF, Grossman HB, Kamat AM. The role of radical cystectomy in patients with clinical T4b bladder cancer. Urol Oncol. 2011 Mar-Apr; 29(2):157-61. PMID: 20456984.
      View in: PubMed
    72. Logothetis CJ, Siefker-Radtke A. Words of wisdom. Re: final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium. Eur Urol. 2010 Apr; 57(4):728-9. PMID: 20965043.
      View in: PubMed
    73. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, Siefker-Radtke A, Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 2009 Dec; 28(3-4):335-44. PMID: 20012924.
      View in: PubMed
    74. Siefker-Radtke AO. Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cure. Expert Rev Anticancer Ther. 2009 Dec; 9(12):1701-3. PMID: 19954279.
      View in: PubMed
    75. Svatek RS, Siefker-Radtke A, Dinney CP. Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy. Can Urol Assoc J. 2009 Dec; 3(6 Suppl 4):S228-31. PMID: 20019991.
      View in: PubMed
    76. Hussain MH, Wood DP, Bajorin DF, Bochner BH, Dreicer R, Lamm DL, O'Donnell MA, Siefker-Radtke AO, Theodorescu D, Dinney CP. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol. 2009 Dec 01; 27(34):5680-4. PMID: 19858384.
      View in: PubMed
    77. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 2009 Aug 15; 15(16):5060-72. PMID: 19671845.
      View in: PubMed
    78. Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE. Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 2009 Jun 01; 27(16):2592-7. PMID: 19414678.
      View in: PubMed
    79. Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke A, Pisters LL, Swanson DA, Dinney CP, Kamat AM. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology. 2009 Jan; 73(1):147-52. PMID: 18848348.
      View in: PubMed
    80. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol. 2008 Sep; 180(3):867-72; discussion 872. PMID: 18635226.
      View in: PubMed
    81. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res. 2008 Mar 01; 14(5):1478-86. PMID: 18316572.
      View in: PubMed
    82. Kassouf W, Spiess PE, Siefker-Radtke A, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer. 2007 Aug 15; 110(4):764-9. PMID: 17614317.
      View in: PubMed
    83. Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer. 2007 Jul 01; 110(1):62-7. PMID: 17542024.
      View in: PubMed
    84. Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke A, Dinney CP, Kamat AM. P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors. Eur Urol. 2007 Sep; 52(3):769-74. PMID: 17434254.
      View in: PubMed
    85. Siefker-Radtke A. Urachal carcinoma: surgical and chemotherapeutic options. Expert Rev Anticancer Ther. 2006 Dec; 6(12):1715-21. PMID: 17181485.
      View in: PubMed
    86. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer. 2006 Nov 01; 107(9):2254-61. PMID: 17029276.
      View in: PubMed
    87. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer. 2006 Aug 01; 107(3):497-505. PMID: 16795067.
      View in: PubMed
    88. Siefker-Radtke A. Systemic chemotherapy options for metastatic bladder cancer. Expert Rev Anticancer Ther. 2006 Jun; 6(6):877-85. PMID: 16761931.
      View in: PubMed
    89. Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, Dinney CP. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol. 2006 Jun; 175(6):2058-62. PMID: 16697803.
      View in: PubMed
    90. Abrahams NA, Moran C, Reyes AO, Siefker-Radtke A, Ayala AG. Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases. Histopathology. 2005 Jan; 46(1):57-63. PMID: 15656887.
      View in: PubMed
    91. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B. Focus on bladder cancer. Cancer Cell. 2004 Aug; 6(2):111-6. PMID: 15324694.
      View in: PubMed
    92. Siefker-Radtke AO, Dinney CP, Abrahams NA, Moran C, Shen Y, Pisters LL, Grossman HB, Swanson DA, Millikan RE. Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol. 2004 Aug; 172(2):481-4. PMID: 15247709.
      View in: PubMed
    93. Siefker-Radtke AO, Walsh GL, Pisters LL, Shen Y, Swanson DA, Logothetis CJ, Millikan RE. Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol. 2004 Jan; 171(1):145-8. PMID: 14665863.
      View in: PubMed
    94. Millikan R, Siefker-Radtke A, Grossman HB. Neoadjuvant chemotherapy for bladder cancer. Urol Oncol. 2003 Nov-Dec; 21(6):464-7. PMID: 14693274.
      View in: PubMed
    95. Sweeney P, Millikan R, Donat M, Wood CG, Radtke AS, Pettaway CA, Grossman HB, Dinney CP, Swanson DA, Pisters LL. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J Urol. 2003 Jun; 169(6):2113-7. PMID: 12771730.
      View in: PubMed
    96. Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF, Smith TL, Williams D, Logothetis CJ. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol. 2002 Mar 01; 20(5):1361-7. PMID: 11870180.
      View in: PubMed
    97. Hsi LC, Tsai AL, Kulmacz RJ, English DG, Siefker AO, Otto JC, Smith WL. Trp387 and the putative leucine zippers of PGH synthases-1 and -2. J Lipid Mediat. 1993 Mar-Apr; 6(1-3):131-8. PMID: 8357979.
      View in: PubMed
    98. Uncommon Cancers of the Bladder. 18-26.
    99. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy. European Urology.
    100. Update of the ICUD-SIU consultation on upper tract urothelial carcinoma 2016. World Journal of Urology. 1-9.
    101. Upper tract urothelial carcinoma topical issue 2016. World Journal of Urology. 1-12.
    102. Uncommon Cancers of the Bladder. 23-33.
    103. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clinical Genitourinary Cancer. 13:218-224.
    104. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy. Urologic Oncology: Seminars and Original Investigations. 34:59.e1-59.e8.
    105. Bladder cancer and upper tracts. 311-333.
    106. Review. Clinical Advances in Hematology and Oncology. 5:889-890.
    107. The state of immune checkpoint inhibition in urothelial carcinoma current evidence and future areas of exploration. Cancer Journal (United States). 22:96-100.
    108. Therapeutic Opportunities in the Intrinsic Subtypes of Muscle-Invasive Bladder Cancer. Hematology/Oncology Clinics of North America. 29:377-394.
    109. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Journal of Urology. 186:453.
    110. Targets by organ site.
    111. Chemotherapy, surgical and radiation options for metastatic bladder cancer. 355-376.
    112. A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers. Molecular Therapy.
    113. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. European Urology.
    114. Editorial Comment. Journal of Urology.
    115. Chemotherapy. 179-189.
    116. Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients with Unresectable or Metastatic Urothelial Cancer and Poor Renal Function. Urology. 89:83-89.
    117. Urachal carcinoma. Human Pathology. 46:1808-1814.
    118. National comprehensive cancer network recommendations on molecular profiling of advanced bladder cancer. Journal of Clinical Oncology. 34:3346-3348.
    119. Bladder cancer. 143-152.
    SIEFKER-RADTKE's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description